ArticleJournal of the American Heart Association2026
Plasma S100 Calcium-Binding Protein A8/A9 and Cognitive Impairment After Acute Ischemic Stroke.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundS100A8/A9 (S100 calcium-binding protein A8/A9) was suggested to play pathophysiological roles in the amyloid-neuroinflammatory cascade, contributing to cognitive impairment. However, little is known about the impacts of S100A8/A9 on poststroke cognitive impairment. We aimed to prospectively investigate the relationships between baseline plasma S100A8/A9 levels with cognitive impairment among patients with acute ischemic stroke.
methodsOur prospective cohort study included patients with acute ischemic stroke from an ancillary study of CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). At the 3-month follow-up, cognitive impairment was evaluated using the Montreal Cognitive Assessment and the Mini-Mental State Examination. Logistic regression analysis was conducted to estimate the association between S100A8/A9 and the risk of poststroke cognitive impairment (PSCI).
resultsA total of 618 participants were included, of whom 405 (65.5%) met the criteria for PSCI on the basis of the Montreal Cognitive Assessment, and 323 (52.3%) on the basis of the Mini-Mental State Examination. After adjusting for potential confounding factors, especially high-sensitivity C-reactive protein, the odds ratios of PSCI for participants in the highest tertile of plasma S100A8/A9 levels were 2.27 (95% CI, 1.37-3.75) for Montreal Cognitive Assessment-defined PSCI and 1.62 (95% CI, 1.01-2.60) for Mini-Mental State Examination-defined PSCI, compared with the lowest tertile. We observed that higher baseline levels of S100A8/A9 were associated with an increased risk of cognitive impairment in a linear dose-response manner (
conclusionsHigher baseline plasma levels of S100A8/A9 were associated with an increased risk of PSCI, suggesting the potential role of S100A8/A9 as a valuable predictive biomarker for PSCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.